Alright, imagine you're playing with building blocks. You have a special set of instructions that helps you make really cool things. Abeona is like those instructions.

Now, some kids might find it hard to understand the instructions on their own, so they need help from someone who knows this game really well. That's what Abeona does - it makes sure everyone can build and create with their special set of 'blocks' as they learn more about how to use them properly.

Sometimes, even the helper kid might make a small mistake or think something will work a different way than intended. When that happens, we say "Be careful!" so they don't knock down all the cool buildings they've made so far. That's what people mean by "risk" and "careful". Read from source...

As AI, I've analyzed the provided text and here are my points based on your instructions:

1. **Inconsistencies:**
- There are no major inconsistencies in the given text, which is a press release about Abeona Therapeutics Inc.

2. **Biases:**
- The text appears to be unbiased as it's not explicitly favoring or opposing any particular viewpoint.
- However, it is biased towards presenting information positively about Abeona Therapeutics Inc., which is typical of a press release issued by a company.

3. **Irrational Arguments:**
- There are no irrational arguments presented in the text.

4. **Emotional Behavior/language:**
- The text maintains a professional tone and does not exhibit emotional behavior or language, other than the use of the word "exciting" when mentioning the company's products: "Abeona has an exciting product pipeline."
- However, this use of emotionally charged language is common in marketing and promotional materials like press releases.

Here are a few specific points to consider:

- The text uses superlatives like "leading" and " cutting-edge" to describe the company's technology platform. While these terms might be subjective or overstate the facts, they're commonly used in similar press releases.
- The use of all-capital letters for "BENZINGA.com" could be seen as an attempt to grab attention or imply importance, which could be considered emotionally charged.
- The text includes a stock price and percentage change, which might evoke emotional responses from investors but is standard practice in financial news.

In conclusion, while the text maintains a professional tone overall, it employs some common biased and emotionally charged language typically found in press releases focused on promoting a company's achievements and potential.

The sentiment of the provided article is mostly **neutral** with a slight lean towards **positive**. Here's why:

1. The article announces that Abeona Therapeutics Inc has submitted a Marketing Authorisation Application to the European Medicines Agency for ABEXTA, its proprietary gene therapy for treating MPS IIIA.
2. This submission marks an important milestone as the company seeks approval for its product in Europe.
3. There's no mention of any setbacks or negative developments in the article.

While the news is neither extremely positive nor negative, it does reflect a proactive step taken by Abeona Therapeutics, suggesting a slightly positive sentiment overall.

Based on the information provided, here's a comprehensive investment recommendation with associated risks for Abeona Therapeutics Inc (ABEA):

**Investment Thesis:**

Abeona Therapeutics (ABEA) is a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases. The company has three lead programs: ABO-102 and ABO-101 for Sanfilippo syndrome Types A and B, respectively, and EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).

ABEA's portfolio holds promising potential as gene therapies have shown remarkable results in treating rare genetic diseases, with high unmet need and significant commercial opportunities. However, the company faces several hurdles and risks that investors should be aware of.

**Investment Recommendation:**

*Recommendation: Speculative BUY (12-month target price: $8.50)*

*Stop-loss: $4.50*

**Risks & Considerations:**

1. **Clinical Trial Risk:**
- Pivotal phase 3 clinical trial results for ABO-102 and ABO-101 are expected in late 2023 or early 2024.
- Failure to demonstrate statistical significance, safety, or improved benefit-risk profile could negatively impact ABEA's share price.

2. **Regulatory Risk:**
- The FDA or other regulatory authorities' approval decisions for ABEA's gene therapies are uncertain until final data readouts and regulatory submissions.
- A lack of confidence in submission packages or potential safety concerns could result in delays or rejection.

3. **Manufacturability & Scalability:**
- Gene therapy production faces unique challenges, including complex manufacturing processes and high costs per dose.
- Issues with scalability or quality control could limit ABEA's commercial potential.

4. **Financial Risk:**
- As a clinical-stage company, ABEA has yet to generate material revenue.
- Sufficient cash runway is dependent on successful financing efforts, which may not be assured in the future given the market conditions and company performance.

5. **Market & Competition Risk:**
- The gene therapy landscape is rapidly evolving with intense competition from well-funded biopharmaceutical companies such as Pfizer (PFE), Spark Therapeutics (ONCE), and Novartis (NVS).
- ABEA must demonstrate clinical superiority to capture market share.

6. **Technological & Scientific Risk:**
- Despite the promise of gene editing technologies like CRISPR-Cas9, their long-term safety and efficacy are still being evaluated.
- Potential technological or scientific breakthroughs could challenge ABEA's approach or render its therapies obsolete.

In conclusion, Abeona Therapeutics (ABEA) offers exposure to a rapidly growing market with substantial unmet need. However, significant risks remain until successful pivotal data readouts, regulatory approvals, and commercial execution are assured. Investors should conduct thorough due diligence and consider their risk tolerance before investing in ABEA.